Heparin-induced thrombocytopenia: Pathogenesis, diagnosis and treatment;Thrombopénies et thromboses induites par l'héparine: Physiopathologie, diagnostic et traitement

Revue de Medecine Interne

Volumn 25, Issue 1, 2004, Pages 35-45

  Gruel, Y ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

Danaparoid sodium; Heparin; Hirudin; Low molecular weight heparin; Thrombocytopenia

Indexed keywords

ANTICOAGULANT AGENT; DANAPAROID; FONDAPARINUX; HEPARIN; ILOPROST; LEPIRUDIN; TIROFIBAN; WARFARIN; XIMELAGATRAN;

BLEEDING; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; KIDNEY FAILURE; PATHOGENESIS; REVIEW; SIDE EFFECT; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT WITHDRAWAL;

EID: 1242296245     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(03)00109-7     Document Type: Short Survey

References (64)

1. Gruel Y., Pouplard C. Physiopathologie des thrombopénies et des thromboses induites par l'héparine. Hématologie. 8:2002;241-252.
2. Warkentin T.E., Chong B.H., Greinacher A. Heparin-induced thrombocytopenia: Towards consensus. Thromb Haemost. 79:1998;1-7.
3. Amiral J., Bridey F., Dreyfus M., Vissac A., Fressinaud E., Wolf M., et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 68:1992;95-96.
4. Greinacher A., Michels I., Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost. 67:1992;545-549.
5. Kelton J., Smith J., Warkentin T., Hayward C., Denomme G., Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. 83:1994;3232-3239.
6. Pouplard C., May M.A., Iochmann S., Amiral J., Vissac A.M., Marchand M., et al. Antibodies to platelet factor 4, Heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin, Clinical implications for heparin-induced thrombocytopenia. Circulation. 99:1999;2530-2536.
7. Brandt J., Isenhart C., Osborne J., Ahmed A., Anderson C. On the role of platelet FcγRIIa phenotype in heparin-induced thrombocytopenia. Thromb Haemost. 74:1995;1564-1572.
8. Carlsson L.E., Santoso S., Baurichter G., Kroll H., Papenberg S., Eichler P., et al. Heparin-induced thrombocytopenia: New insights into the impact of the FcgRIIa-R-H131 polymorphism. Blood. 92:1998;1526-1531.
9. Arepally G., McKenzie S.E., Jiang X.M., Poncz M., Cines D.B. Fc gamma RIIA H/R(131) polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood. 89:1997;370-375.
10. Amiral J., Wolf M., Fischer A.M., Boyer-Neumann C., Vissac A.M., Meyer D. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol. 92:1996;954-959.
11. Amiral J., Marfaing-Koka A., Wolf M., Alessi M.C., Tardy B., Boyer-Neumann C., et al. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood. 88:1996;410-416.
12. Lee D.H., Warkentin T.E., Denomme G.A., Hayward C.P.M., Kelton J.G. A diagnostic test for heparin-induced thrombocytopenia: Detection of platelet microparticles using flow cytometry. Br J Haematol. 95:1996;724-731.
13. Cines D., Tomaski A., Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J M. 316:1987;581-589.
14. Pouplard C., Iochmann S., Renard B., Herault O., Colombat P., Amiral J., et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood. 97:2001;3300-3302.
15. Lee D.H., Warkentin T.E. Frequency of Heparin-induced Thrombocytopenia. Warkentin T.E., Greinacher A. Heparin-Induced Thrombocytopenia. Second :2001;87-121 Basel: Marcel Dekker, Inc, New York.
16. Girolami B., Prandoni P., Stefani P.M., Tanduo C., Sabbion P., Eichler P., et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin, A prospective cohort study. Blood. 101:2003;2955-2959.
17. Bauer T.L., Arepally G., Konkle B.A., Mestichelli B., Shapiro S.S., Cines D.B., et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation. 95:1997;1242-1246.
18. Trossaert M., Gaillard A., Commin P.L., Amiral J., Vissac A.M. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol. 101:1998;653-655.
19. Warkentin T.E., Sheppard J.A., Horsewood P., Simpson P.J., Moore J.C., Kelton J.G. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 96:2000;1703-1708.
20. deRaucourt E., Vinsonneau C., Juvin K., Fischer A.M., Meyer G. Heparin-induced thrombocytopenia with thrombotic complications during prophylactic treatment with low-molecular-weight heparin. Blood Coagulat Fibrinol. 7:1996;786-788.
21. Eichinger S., Kyrle P., Brenner B., Wagner B., Kapiotis S., Lechner K., et al. Thrombocytopenia associated with low-molecular weight heparin. Lancet. 337:1991;1425-1426.
22. Elalamy I., Potevin F., Lecrubier C., Bara L., Marie J., Samama M. A fatal low-molecular-weight heparin-associated thrombocytopenia after hip surgery: possible usefulness of PF4-heparin Elisa test. Blood Coag Fibrinol. 7:1996;665-671.
23. Warkentin T., Levine M., Hirsh J., Horsewood P., Roberts R., Gent M., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J M. 332:1995;1330-1335.
24. Denomme G.A. The platelet Fc receptor in Heparin-induced Thrombocytopenia. Warkentin T.E., Greinacher A. Heparin-Induced Thrombocytopenia. Second :2001;189-214 Basel: Marcel Dekker, Inc, New York.
25. Warkentin T.E. Clinical picture of Heparin-induced Thrombocytopenia. Warkentin T.E., Greinacher A. Heparin-Induced Thrombocytopenia. Second :2001;43-86 Basel: Dekker M., Inc, New York.
26. Warkentin T.E., Kelton J.G. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern M. 135:2001;502-506.
27. Zalcberg J., McGrath K., Dauer R., Wiley J. Heparin-induced thrombocytopenia with associated disseminated intravascular coagulation. Br J Haematol. 54:1983;655-660.
28. Warkentin T.E., Kelton J.G. A 14-year studyof heparin-induced thrombocytopenia. Am J M. 101:1996;502-507.
29. Towne J., Bernhard V., Hussey C., Garancis J. White clot syndrome. Peripheral vascular complications of heparin therapy. Arch Surg. 114:1979;372-377.
30. Warkentin T.E. Heparin-induced thrombocytopenia: A ten-year retrospective. Annu Rev M. 50:1999;129-147.
31. Warkentin T.E., Elavathil L.J., Hayward C.P., Johnston M.A., Russett J.I., Kelton J.G. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern M. 127:1997;804-812.
32. Tardy B., Tardy-Poncet B., Fournel P.C.V., Jospe R., Dacosta A. Lower limbs veins should be sytematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb Haemostas. 82:1999;1199-2000.
33. Hong A.P., Cook D.J., Sigouin C.S., Warkentin T.E. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood. 101:2003;3049-3051.
34. Warkentin T.E. Heparin-induced skin lesions. Br J Haematol. 92:1996;494-497.
35. Warkentin T., Hirte H., Anderson D., Wilson W., O'Connell G., Lo R. Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am J M. 97:1994;489-491.
36. Delhumeau A., Moreau X., Chapotte C., Houi N., Bigorgne J. Heparin-associated thrombocytopenia syndrome: an underestimated etiology of adrenal hemorrhage. Intensive Care M. 19:1993;475-477.
37. Warkentin T.E. Venous thromboembolism in heparin-induced thrombocytopenia. Curr Opin Pulm M. 6:2000;343-351.
38. Warkentin T.E., Greinacher A. Laboratory testing for Heparin-induced Thrombocytopenia. Warkentin T.E., Greinacher A. Heparin-Induced Thrombocytopenia. Second :2001;231-270 Basel: Marcel Dekker, Inc, New York.
39. Arepally G., Reynolds C., Tomaski A., Amiral J., Jawad A., Poncz M., et al. Comparison of PF4/heparin Elisa assay with the c-14-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 104:1995;648-654.
40. Pouplard C., Amiral J., Borg J.Y., Laporte-Simitsidis S., Delahousse B., Gruel Y. Decision analysis for use of platelet aggregation test., carbon 14 serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 111:1999;700-706.
41. Regnault V., De Maistre E., Carteaux J.P., Gruel Y., Nguyen P., Tardy B., et al. Platelet activation induced by human antibodies to interleukin-8. Blood. 101:2003;1419-1421.
42. Sheridan D., Carter C., Kelton J. A diagnostic test for heparin-induced thrombocytopenia. Blood. 67:1986;27-30.
43. Warkentin T.E., Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J M. 344:2001;1286-1292.
44. Greinacher A., Volpel H., Janssens U., HachWunderle V., KemkesMatthes B., Eichler P., et al. Recombinant hirudin (Lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia, A prospective study. Circulation. 99:1999;73-80.
45. Greinacher A., Warkentin T.E. Treatment of heparin-induced thrombocytopenia: An overview. Warkentin T.E., Greinacher A. Heparin-induced thrombocytopenia. 2nd :2001;291-322 Basel: Marcel dekker, Inc, New York.
46. Chong B., Magnani H. Danaparoid for the treatment of heparin-induced thrombocytopenia. Warkentin T.E., Greinacher A. Heparin-induced thrombocytopenia. 2001;323-347 Basel: Marcel dekker., Inc, New York.
47. Tardy-Poncet B., Tardy B., Reynaud J., Mahul P., Mismetti P., Mazet E., et al. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. Chest. 115:1999;1616-1620.
48. Greinacher A., Eichler P., Lubenow N., Kwasny H., Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 96:2000;846-851.
49. Greinacher A., Lubenow N. Recombinant Hirudin in Clinical Practice: Focus on Lepirudin. Circulation. 103:2001;1479-1484.
50. Farner B., Eichler P., Kroll H., Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost. 85:2001;950-957.
51. Eichler P., Friesen H.J., Lubenow N., Jaeger B., Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood. 96:2000;2373-2378.
52. Potzsch B., Madlener K., Seelig C., Riess C., Greinacher A., Muller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass, assessment of the whole blood ecarin clotting time. Thromb Haemost. 77:1997;920-925.
53. Kappa J., Fisher C., Todd B., Stenach N., Bell P., Campbell F., et al. Intraoperative management of patients with heparin-induced thrombocytopenia. Ann Thorac Surg. 49:1990;714-722.
54. Aouifi A., Blanc P., Piriou V., Bastien O.H., Ffrench P., Hanss M., et al. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia. Ann Thorac Surg. 71:2001;678-683.
55. Koster A., Kukucka M., Bach F., Meyer O., Fischer T., Mertzlufft F., et al. Anticoagulation during cardiopulmonary bypass in patients with heparin, induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. Anesthesiology. 94:2001;245-251.
56. Amiral J., Lormeau J.C., Marfaing-Koka A., Vissac A.M., Wolf M., Boyer-Neumann C., et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagulat Fibrinol. 8:1997;114-117.
57. Addonizio V., Fisher C., Kappa J., Ellison N. Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK36374). Surgery. 102:1987;796-807.
58. Grocott H., Root J., Berkowitz S., de Bruijn N., Landolfo K. Coagulation complication cardiopulmonary bypass in patient with heparin-induced thrombocytopenia receiving the heparinoid., danaparoid sodium. J Cardiothorac Vasc Anesthesiol. 11:1997;875-877.
59. Longrois D., De Maistre E., Bischoff N., Dopff C., Meistelman C., Angioi M., et al. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia. Can J Anaesth. 47:2000;255-260.
60. Fischer K.G. Hemodialysis in heparin-induced thrombocytopenia. Warkentin T.E., Greinacher A. Heparin-induced thrombocytopenia. 2001;409-427 Basel: Marcel dekker, Inc, New York.
61. Fischer K.G., van de Loo A., Bohler J. Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int. 56:(Suppl 72):1999;S46-S50.
62. Greinacher A., Eckhardt T., Mussmann J., Mueller-Eckhardt C. Pregnancy complicated by heparin associated thrombocytopenia: management by a prospectively in vitro selected heparinoid (Org 10172). Thromb Res. 71:1993;123-126.
63. Macchi L., Sarfati R., Guicheteau M., Chamlian V., Pourrat O., Gruel Y., et al. Thromboembolic prophylaxis with danaparoid (Orgaran) in a high, thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia (HIT) and Widal's disease. Clin Appl Thromb Hemost. 6:2000;187-189.
64. Gruel Y., Lang M., Darnige L., Pacouret G., Dreyfus X., Leroy J., et al. Fatal effect of re-exposure to heparin after previous heparin-associated thrombocytopenia and thrombosis. Lancet. 336:1990;1077-1078.